Recent Updates
Recently added Catalysts
INDV Neutral Sentiment Score: 60/100

Indivior Announces FY and Q4 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor...

Key Takeaway: Indivior PLC has announced its financial results for the fiscal year and the fourth quarter ending December 31, 2024. The earnings release includes a live webcast presentation hosted by CEO Mark Crossley. Indivior continues its dedication to addressing substance use disorders with a focus on evidence-based treatment and expanding its product pipeline. The company operates globally, with its products available in over 30 countries.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its financial results for the period ending December 31, 2024.
  • The company continues to focus on developing treatments for substance use disorders.
  • Indivior's global portfolio of OUD treatments is well-established.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am ET ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/bfut8veu Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIb27314d7848f43e682309a38029a2114 (Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond , VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What are the financial results released by Indivior for 2024?

Indivior announced its financial results for the period ending December 31, 2024.

When is the Indivior webcast presentation scheduled?

The webcast presentation is on February 20, 2025, at 13:00 BST (8:00 am ET).

What is Indivior's main focus in the pharmaceutical industry?

Indivior focuses on developing medicines to treat substance use disorders (SUD).

Where is Indivior headquartered?

Indivior is headquartered in Richmond, Virginia, United States.

How many countries is Indivior's portfolio available in?

Indivior's portfolio of products is available in over 30 countries worldwide.

Last updated: Feb 20, 2025